Something went wrong with the connection!
 Breaking News

FDA approves TB pill that cures more hard-to-treat patients

FDA approves TB pill that cures more hard-to-treat patients
August 20
13:11 2019

TRENTON, New Jersey: US regulators have approved a new tuberculosis medicine that shortens and improves treatment for the hardest-to-treat cases, a worsening problem in many poor countries. It’s the first TB drug from a non-profit group, the TB Alliance. Formed to come up with better treatments, the group developed pretomanid with help from charities and government agencies.

The pill was approved by the Food and Drug Administration August 14 for use with two other antibiotics. Decades of incomplete or ineffective treatment has resulted in TB strains that have become drug-resistant and aren’t killed by long-standard medicines.
In a key study, the three-pill combo cured about 90 per cent of patients with very drug-resistant TB, usually within six months. Patients also infected with HIV, a common situation, fared as well as the other study participants. Pretomanid also appears to stop patients from spreading the deadly bacterial infection after just a few days’ treatments.

Until now, the best option cured about two-thirds of patients took 18 to 30 months and required up to eight kinds of shots and pills. Many patients die or don’t finish treatment, according to TB Alliance CEO Mel Spigelman.
Worldwide, TB kills about 1.6 million people annually. It spreads through droplets when someone sick with TB sneezes or coughs. TB attacks the lungs and sometimes other organs.

Pretomanid was approved for use with Zyvox and Sirturo, two other antibiotics used for the toughest cases. The three drugs, which have little known resistance, attack tuberculosis in different ways. Potential side effects include liver damage, nerve pain and an irregular heartbeat.
The new combo could help over 75,000 patients per year, mostly in India, China, Indonesia, South Africa and Nigeria, Spigelman said. The FDA is the first regulator to approve pretomanid, though there aren’t many severe cases in the US. The FDA’s action should bring quick approval in countries where it’s endemic.

The alliance will work with the World Health Organization to speed adoption of the treatment in those countries. The alliance is contracting with multiple generic manufacturers to make pretomanid and keep it affordable. AP

Comments

comments

Related Articles

Polls

Will SAARC cooperation improve due to COVID19 crisis

View Results

Loading ... Loading ...

E-paper Latest Edition

Subscribe to our Digital Edition

Epaper

ADVERTISEMENT – DR HORTON

Dr Horton Skyline Ridge

ADVERTISEMENT – SEVEN JACPOTS

casino

ADVERTISEMENT – BETRALLY INDIA

betting India

ADVERTISEMENT – DR HORTON

ADVERTISEMENT – Mountain House

Mounatin House

ADVERTISEMENT – Star Tours

Star Tours

ADVERTISEMENT – INKASA INTERIORS

Inkasa Interiors | Interior Designer in Delhi

50 SPIRITUAL APPETIZERS – VINOD DHAWAN

50-ad-Indiapost

It’s a lovely book. It feels energetically clear and light. It’s easy to read, dip in and out and most importantly it offers information without fluff! Blessings on this project.

Jac O’Keeffe
Spirituality teacher based in USA.

*Available on Amazon, Flipkart & other online stores*

ADVERTISEMENT – JOBSORA- FIND A JOB NOW!

Jobsora Jobs

Follow us On Twitter

Follow lockdown, says PM in 'Mann Ki Baat' - https://t.co/WLw6nS6BXt Get your news featured use #IndiaPostUSA… https://t.co/oJVe7ssjSw
h J R
@Indiapost_News
Stop movement of people across cities, seal borders: Centre to states - https://t.co/8p9RnEio9p Get your news feat… https://t.co/On6iMXgpkr
h J R
@Indiapost_News
Indian-American woman charged for killing her son - https://t.co/ZhMiER1ews Get your news featured use… https://t.co/6xmwB9BFv2
h J R
@Indiapost_News
Evacuate #Sikhs stranded in #Afghanistan: Punjab #CM - https://t.co/3tD7K5RyKU Get your news featured use… https://t.co/TeGm8WMzTD
h J R
@Indiapost_News

POPULAR CATEGORIES

Subscribe To Our Mailing List

Enter your email address:

Delivered by FeedBurner

Subscribe to IndiaPost by Email

Download Media Kit

India Post Media Kit